Day 1: June 19, 2025

Policy & advocacy to support the implementation of comprehensive genomic profiling for metastatic cancer patients in Canada.

9:30 a.m. – 9:45 a.m. ET

Conference Day 1 Opening

9:45 a.m. – 10:00 a.m. ET

Welcome from CCRAN’s President & CEO

10:00 a.m. – 10:30 a.m. ET

Collective Advocacy Efforts for Equitable Access to Biomarker Testing for Metastatic Cancer Patients in Canada (Presentation)

10:30 a.m. – 11:15 a.m. ET

Key Learnings from CCRAN’s 2024 Biomarkers Conference: Toward Timely and Equitable Advanced Biomarker Testing for Patients with Metastatic Cancer in Canada (Presentation)

11:15 a.m. – 12:00 p.m. ET

Health Break

12:00 p.m. – 1:15 p.m. ET

Generating a Cost-Benefit Analysis to Support Access to Comprehensive Genomic Profiling (CGP) for Five Metastatic Cancers in Canada: Helping to Ensure CGP Becomes a Standard of Care in Canada! (Keynote Presentation)

1:15 p.m. – 2:30 p.m. ET

Reacting to the Findings of CCRAN’s Cost-Benefit Analysis Report: The Value of Accessing Comprehensive Genomic Profiling for Cancer Patients in Canada (Patient Advocacy Group Roundtable)

2:30 p.m. – 2:45 p.m. ET

Health Break

2:45 p.m. - 3:45 p.m. ET

What Can We Learn from Early Adopters of Comprehensive Genomic Profiling? An International Discussion

3:45 p.m. - 4:15 p.m. ET

The State of Readiness Progress Report 2.0 (Presentation)

4:15 p.m. - 5:15 p.m. ET

What Will it Take to Implement Comprehensive Genomic Profiling as a Standard of Care in Canada for the Management of Metastatic Disease in Cancer Patients? 

5:15 p.m. – 5:30 p.m. ET

Glance at Day 2. Closing Remarks from CCRAN’s President & CEO 

Day 2: June 20, 2025

The future of comprehensive genomic profiling & precision medicine in clinical practice.

9:30 a.m. – 9:40 a.m. ET

Conference Day 2 Opening

9:45 a.m. – 10:00 a.m. ET

Welcome from CCRAN’s President & CEO

10:00 a.m. – 10:30 a.m. ET

Reviewing the Findings of a National Canadian Clinician Survey: Understanding the Utility of Comprehensive Genomic Profiling in Clinical Practice Across Multiple Tumour Types (Presentation)

10:30 a.m. – 11:30 a.m. ET

It Starts at the Lab: Towards Establishing National Standards for the Performance, Integration, Coordination and Communication of Biomarker Testing Results 

11:30 p.m. - 12:15 p.m. ET

Health Break

12:15 p.m. - 1:30 p.m. ET 

Why Access Comprehensive Genomic Profiling? The Many Promising Therapeutic Benefits of a Genome-First Approach (Clinician Roundtable)

1:30 p.m. – 2:30 p.m. ET

Activating the Immune Response: Exploring Novel Avenues of Immunotherapy

2:30 p.m. – 2:45 p.m. ET

Health Break

2:45 p.m. – 3:45 p.m. ET

Innovative A.I. Based Technology in the Management of Metastatic Cancer 

3:45 p.m. – 4:15 p.m. ET

Coming in ‘Hot’: The Future of Radioligand Therapies in Canada (Presentation)

4:15 p.m. – 4:45 p.m. ET

The Value of Partnerships to Drive Innovation in Health Care Systems

4:45 p.m. – 5:00 p.m. ET

Day 2 Closing Remarks and Conference Adjournment.